Quinn KA, Dashora H, Novakovich E, et al. - Researchers aimed at determining the time-dependent effects of tocilizumab on vascular inflammation as estimated by ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) in GCA. From a prospective, observational cohort, they included 25 patients with GCA treated with tocilizumab. FDG-PET was conducted in patients at the baseline visit prior to initiation of tocilizumab and at subsequent follow-up visits at 6-month intervals. Findings revealed both clinical improvement and reduction of vascular inflammation as measured by serial FDG-PET among patients with GCA in correlation with tocilizumab treatment.